CA2922013A1 - Inducteurs chimiques d'hemoglobine foetale - Google Patents

Inducteurs chimiques d'hemoglobine foetale Download PDF

Info

Publication number
CA2922013A1
CA2922013A1 CA2922013A CA2922013A CA2922013A1 CA 2922013 A1 CA2922013 A1 CA 2922013A1 CA 2922013 A CA2922013 A CA 2922013A CA 2922013 A CA2922013 A CA 2922013A CA 2922013 A1 CA2922013 A1 CA 2922013A1
Authority
CA
Canada
Prior art keywords
thalassemia
agent
beta
hbf
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2922013A
Other languages
English (en)
Other versions
CA2922013C (fr
Inventor
Susan P. Perrine
Douglas V. Faller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phoenicia Biosciences Inc
Original Assignee
Phoenicia Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phoenicia Biosciences Inc filed Critical Phoenicia Biosciences Inc
Priority to CA3120111A priority Critical patent/CA3120111A1/fr
Publication of CA2922013A1 publication Critical patent/CA2922013A1/fr
Application granted granted Critical
Publication of CA2922013C publication Critical patent/CA2922013C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2922013A 2013-08-20 2014-08-20 Inducteurs chimiques d'hemoglobine foetale Active CA2922013C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3120111A CA3120111A1 (fr) 2013-08-20 2014-08-20 Inducteurs chimiques d'hemoglobine foetale

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361867965P 2013-08-20 2013-08-20
US61/867,965 2013-08-20
PCT/US2014/051887 WO2015026939A1 (fr) 2013-08-20 2014-08-20 Inducteurs chimiques d'hémoglobine foetale

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3120111A Division CA3120111A1 (fr) 2013-08-20 2014-08-20 Inducteurs chimiques d'hemoglobine foetale

Publications (2)

Publication Number Publication Date
CA2922013A1 true CA2922013A1 (fr) 2015-02-26
CA2922013C CA2922013C (fr) 2021-06-08

Family

ID=52484128

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2922013A Active CA2922013C (fr) 2013-08-20 2014-08-20 Inducteurs chimiques d'hemoglobine foetale
CA3120111A Pending CA3120111A1 (fr) 2013-08-20 2014-08-20 Inducteurs chimiques d'hemoglobine foetale

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3120111A Pending CA3120111A1 (fr) 2013-08-20 2014-08-20 Inducteurs chimiques d'hemoglobine foetale

Country Status (2)

Country Link
CA (2) CA2922013C (fr)
WO (1) WO2015026939A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007249827A1 (en) * 2006-05-09 2007-11-22 Colorado State University Research Foundation Methods for treating blood disorders
US20110015168A1 (en) * 2007-01-19 2011-01-20 Mitchell Keegan Methods for increasing levels of human fetal hemoglobin

Also Published As

Publication number Publication date
WO2015026939A1 (fr) 2015-02-26
CA3120111A1 (fr) 2015-02-26
CA2922013C (fr) 2021-06-08

Similar Documents

Publication Publication Date Title
WO2012031125A2 (fr) Inversion des effets d'une anesthésie générale par administration de phénidate de méthyle, d'amphétamine, de modafinil, d'amantadine, et/ou de caféine
EP3316877B1 (fr) Analogues de la cystéamine résistant à l'ado et utilisations de ceux-ci
US20150125526A1 (en) Use of Cysteamine and Derivatives Thereof to Treat Mitochondrial Diseases
WO2012142413A2 (fr) Compositions à base de nitrite et leurs utilisations
EP3558286B1 (fr) Citrulline pour le traitement d'une crise de drépanocytose
KR20210139293A (ko) 폐동맥 고혈압 및 연관 폐동맥 고혈압 치료방법 및 매일 투여
EP4048284B1 (fr) Procédé pour le traitement du cancer
US9018176B2 (en) Inducers of hematopoiesis and fetal globin production for treatment of cytopenias and hemoglobin disorders
AU2021271500A1 (en) Composition containing sesamin or like and NR and/or NMN
US10111846B2 (en) S isomers of alpha-methyl-hydrocinnamic acid for the treatment of blood disorders
CA2922013C (fr) Inducteurs chimiques d'hemoglobine foetale
KR101436644B1 (ko) 당뇨병 치료제
CA3218585A1 (fr) Composition pour le traitement d'etats pathologiques auto-immuns, allo-immuns, inflammatoires et mitochondriaux, et leurs utilisations
RU2538666C2 (ru) Препарат для нормализации процессов перекисного окисления липидов у животных
KR20180033957A (ko) 칼콘 유도체 화합물, 이의 광학이성질체, 또는 이의 약학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 미토콘드리아의 산소 소모율 감소에 의해 야기되는 질환의 예방 또는 치료용 약학 조성물
US8685952B2 (en) Method for the treatment of diabetes
WO2007037258A1 (fr) Agent thérapeutique destiné au trouble déficitaire de l’attention avec hyperactivité
TW202421123A (zh) Hdac抑制劑oki-179用於治療由mapk路徑突變引起之癌症
HK40123764A (zh) 包括sglt抑制剂的组合物及其用途
AU2023314929A1 (en) Therapy selection and treatment of neurodegenerative disorders
CA3259920A1 (fr) Composition pour le dosage intermittent d'inhibiteurs de la calcineurine
HK40075135B (zh) Sglt抑制剂及其用途
US20190151315A1 (en) Drug For Preventing Or Treating Lactic Acidosis
HK40002147A (en) Drug for preventing or treating lactic acidosis
El Messaoudi et al. PP164—Dipyridamole Does Not Limit Myocardial Ischemia-Reperfusion Injury After Coronary Artery Bypass Grafting Regardless AMPD1 Genotype

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160219

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - SMALL

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250214

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250214

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250214

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - SMALL

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250728

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250728

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260223